natgillin/translations-raw huggingface dataset:
In addition, tigecycline did not show NADPH-dependency in the inhibition of CYP2C9, CYP2C19, CYP2D6 and CYP3A, suggesting the absence of mechanism-based inhibition of these CYP enzymes.
Poleg tega tigeciklin pri inhibiciji CYP2C9, CYP2C19, CYP2D6 in CYP3A ni kazal odvisnosti od NADPH, kar kaže na odsotnost encimskega mehanizma inhibicije teh CYP encimov.
The other ingredients are lactose monohydrate, hydrochloric acid, and sodium hydroxide.
Druge sestavine zdravila so laktoza monohidrat, klorovodikova kislina in natrijev hidroksid.
In clinical trials, the most common medicinal product-related treatment emergent adverse reactions were reversible nausea (21 %) and vomiting (13 %), which usually occurred early (on treatment days 1-2) and were generally mild or moderate in severity.
V kliničnih preskušanjih sta bila najpogostejša neželena učinka, ki sta se pojavila v zvezi z zdravljenjem z zdravilom, reverzibilna navzea (21 %) in bruhanje (13 %), ki sta se navadno pojavila v začetku zdravljenja (prvi ali drugi dan zdravljenja) in sta bila na splošno blaga do zmerna.
In rats receiving single or multiple doses of
Pri podganah, ki so prejele bodisi enkraten odmerek bodisi po več odmerkov
Powder for solution for infusion (powder for infusion).
prašek za raztopino za infundiranje (prašek za infuzijo)
These effects were observed at exposures of 14 and 3 times the human daily dose based on the AUC in rats and dogs respectively.
Te učinke so opazovali pri izpostavljenosti, ki je bila 14-krat oziroma 3-krat večja od dnevnega odmerka za ljudi na podlagi AUC pri podganah oziroma psih.
Concomitant administration of tigecycline and warfarin (25 mg single-dose) to healthy subjects resulted in a decrease in clearance of R-warfarin and S-warfarin by 40 % and 23 %, and an increase in AUC by 68 % and 29 %, respectively.
Sočasno dajanje tigeciklina in varfarina (v enkratnem 25-miligramskem odmerku) zdravim osebam je povzročilo zmanjšanje očistka R-varfarina in S-varfarina za 40 % oziroma 23 % in zvečanje AUC za 68 % oziroma 29 %.
Concurrent use of antibiotics with oral contraceptives may render oral contraceptives less effective.
Sočasna uporaba antibiotikov s peroralnimi kontraceptivi lahko zmanjša učinkovitost peroralnih kontraceptivov.
C-labelled tigecycline indicate that tigecycline is excreted readily via the milk of lactating rats.
C, kažejo, da se tigeciklin z lahkoto izloča preko mleka doječih podgan.
• Low protein levels in the blood
• znižana raven beljakovin v krvi
Limited experience is also available in treating patients with concurrent bacteraemia (5.6 %).
Na voljo je tudi malo izkušenj z zdravljenjem bolnikov s sočasno bakteriemijo (5,6 %).
AST and ALT abnormalities in tigecycline-treated patients were reported more frequently in the post therapy period than in those in comparator-treated patients, which occurred more often on therapy.
O nenormalnostih AST in ALT pri bolnikih, zdravljenih s tigeciklinom, so pogosteje poročali v obdobju po končanem zdravljenju kot pri bolnikih, zdravljenih s primerjalnim zdravilom, pri katerih so se le-te pogosteje pojavljale med zdravljenjem.
Inherently resistant organisms
Naravno odporni organizmi
Other medicines and Tygacil Tell your doctor if you are taking, have recently taken or might take any other medicines.
Obvestite zdravnika, če jemljete, ste pred kratkim jemali ali pa boste morda začeli jemati katerokoli drugo zdravilo.
Pathogens of the family Proteeae (Proteus spp., Providencia spp., and Morganella spp.)
Patogeni družine Proteeae (Proteus spp., Providencia spp.
Bone discolouring was observed in rats which was not reversible after two weeks of dosing.
Pri podganah so opazili obarvanje kosti, ki po dveh tednih dajanja zdravila ni bilo več reverzibilno.
There were a limited number of patients with severe underlying disease such as immunocompromised patients, patients with APACHE II scores  15 (3.3 %), or with surgically apparent multiple intra-abdominal abscesses (11.4 %).
Majhno število bolnikov je imelo hujšo osnovno bolezen, na primer imunsko oslabljeni bolniki, bolniki z ocenami >15 po lestvici APACHE II (3,3 %) ali s kirurško ugotovljenimi multiplimi intraabdominalnimi abscesi (11,4 %).
A limited number of patients were enrolled with co-morbid factors such as diabetes (25.8 %), peripheral vascular disease (10.4 %), intravenous substance abuse (4.0 %), and HIVpositive infection (1.2 %).
Vključeno je bilo majhno število bolnikov s sočasnimi dodatnimi bolezenskimi dejavniki, na primer sladkorno boleznijo (25,8 %), boleznimi perifernega žilja (10,4 %), intravensko zlorabo substanc (4,0 %) in okužbo z virusom HIV (1,2 %).
In clinical pharmacology studies using the therapeutic dosage regimen of 100 mg followed by 50 mg q12h, serum tigecycline steady-state Cmax was 866±233 ng/ml for 30-minute infusions and 634±97 ng/ml for 60-minute infusions.
V kliničnofarmakoloških študijah, v katerih so uporabljali shemo terapevtskega odmerjanja 100 mg, nato pa 50 mg vsakih 12 ur, je bila serumska Cmax tigeciklina v stanju dinamičnega ravnovesja 866 ± 233 ng/ml pri 30-minutnih infuzijah in 634 ± 97 ng/ml pri 60-minutnih infuzijah.
No data are available on whether tigecycline can cross the blood-brain barrier in humans.
Ni podatkov o morebitnem prehajanju tigeciklina skozi krvno-možgansko pregrado pri ljudeh.
The steady-state AUC0-12h was 2349±850 ng•h/ml.
AUC0-12h v stanju dinamičnega ravnovesja je bila 2349 ± 850 ng•h/ml.
There were no clinically relevant differences in the clearance of tigecycline between men and women.
Očistek tigeciklina se med moškimi in ženskami ni klinično pomembno razlikoval.
Underlying diseases
Osnovne bolezni
A dosing regimen of 1.2 mg/kg of tigecycline every 12 hours (to a maximum dose of 50 mg every 12 hours) for children aged 8 to <12 years and of 50 mg every 12 hours for adolescents aged 12 to <18 years would likely result in exposures comparable to those observed in adults treated with the approved dosing regimen.
Shema odmerjanja 1,2 mg/kg tigeciklina vsakih 12 ur (do največjega odmerka 50 mg vsakih 12 ur) pri otrocih, starih od 8 do < 12 let, in 50 mg vsakih 12 ur pri mladostnikih, starih od 12 do < 18 let, bi verjetno privedla do izpostavljenosti, primerljive tistim pri odraslih, zdravljenih z odobreno shemo odmerjanja.
The following active substances should not be administered simultaneously through the same Y-site as tigecycline: Amphotericin B, amphotericin B lipid complex, diazepam, esomeprazole, omeprazole and intravenous solutions that could result in an increase of pH above 7.
Naslednjih učinkovin ni dovoljeno injicirati sočasno skozi isti podaljšek Y kot tigeciklin: amfotericin B, amfotericin B v obliki lipidnega kompleksa, diazepam, esomeprazol, omeprazol in intravenske raztopine, ki bi lahko povzročile zvišanje pH nad 7.
• Low platelet levels in the blood(which may lead to an increased bleeding tendency and bruising/haematoma)
• znižana koncentracija krvnih ploščic v krvi (ki lahko zveča nagnjenost h krvavitvam in povzroči modrice/hematome)
Clinical experience in the use of tigecycline for the treatment of infections in paediatric patients aged 8 years and older is very limited (see sections 4.8 and 5.1).
Kliničnih izkušenj z uporabo tigeciklina za zdravljenje okužb pri pediatričnih bolnikih, starih 8 let ali več, je zelo malo (glejte poglavji 4.8 in 5.1).
Patients who develop superinfections, in particular nosocomial pneumonia, appear to be associated with poorer outcomes.
Kaže, da imajo bolniki, pri katerih se razvijejo superinfekcije, zlasti bolnišnična pljučnica, slabši izid zdravljenja.
Tigecycline, a glycylcycline antibiotic, inhibits protein translation in bacteria by binding to the 30S ribosomal subunit and blocking entry of amino-acyl tRNA molecules into the A site of the ribosome.
Glicilciklinski antibiotik tigeciklin inhibira prepisovanje beljakovin z ribonukleinske kisline (RNA) pri bakterijah, tako da se veže na ribosomsko podenoto 30S in blokira vstop aminoacilnih molekul tRNA na mesto A na ribosomu.
• Jaundice (yellow coloration of the skin), inflammation of the liver
• zlatenica (rumeno obarvanje kože), vnetje jeter
Population PK analysis of both studies identified body weight as a covariate of tigecycline clearance in children aged 8 years and older.
Analiza populacijske farmakokinetike je v obeh študijah pokazala, da je telesna masa sospremenljivka očistka tigeciklina pri otrocih, starih 8 let ali več.
No overall differences in pharmacokinetics were observed between healthy elderly subjects and younger subjects (see section 4.2).
Med zdravimi starejšimi bolniki in mlajšimi osebami niso v celoti gledano opazili nikakršnih razlik v farmakokinetiki (glejte poglavje 4.2).
This prevents incorporation of amino acid residues into elongating peptide chains.
To prepreči vgradnjo aminokislinskih ostankov v podaljšujoče se peptidne verige.
The adverse reaction profile of tigecycline in these 58 subjects was generally consistent with that in adults, with the exception of nausea (48.3 %), vomiting (46.6 %) and elevated lipase in serum (6.9 %) which were seen at greater frequencies in children than in adults.
Profil neželenih učinkov tigeciklina pri teh 58 preiskovancih je bil na splošno skladen s profilom pri odraslih, razen pri navzei (48,3 %), bruhanju (46,6 %) in zvišanju ravni lipaze v serumu (6,9 %), saj so se ti neželeni učinki pri otrocih pojavljali pogosteje kot pri odraslih.
Adverse reactions reported with tigecycline, including clinical trials and post-marketing experience, are tabulated below.
Neželeni učinki, o katerih so poročali pri uporabi tigeciklina, vključno s kliničnimi preskušanji in izkušnjami v obdobju trženja, so navedeni v spodnji preglednici.
This in vitro information is consistent with the lack of effect of tigecycline on digoxin clearance noted in the in vivo drug interaction study described above (see section 4.5).
Ta in vitro informacija je v skladu s pomanjkanjem učinka tigeciklina na očistek digoksina, opaženim v in vivo študiji medsebojnega delovanja zdravil, ki je opisana zgoraj (glejte poglavje 4.5).
Thus, 5 ml of reconstituted solution is equivalent to 50 mg of the active substance.
Zato 5 ml rekonstituirane raztopine ustreza 50 mg učinkovine.
Children and adolescents (8 to 17 years of age) Tigecycline is only to be used to treat patients aged 8 years and older after consultation with a physician with appropriate experience in the management of infectious diseases.
Tigeciklin se lahko uporablja samo za zdravljenje bolnikov, starih 8 let ali več, po posvetovanju z zdravnikom, ki ima ustrezne izkušnje z obravnavo okužb.
If you receive more Tygacil than you should
Če ste prejeli večji odmerek zdravila Tygacil, kot bi smeli
mg/L and R  2 mg/L
(^) mg/l in R > 2 mg/l
As it is known for tetracycline class antibiotics, tigecycline may also induce permanent dental defects (discolouration and enamel defects) and a delay in ossification processes in foetuses, exposed in utero during the last half of gestation, and in children under eight years of age due to the enrichment in tissues with a high calcium turnover and formation of calcium chelate complexes (see section 4.4).
Kot je znano za antibiotike tetraciklinske skupine, lahko tudi tigeciklin povzroči trajne okvare zob (obarvanje in okvare sklenine) in zakasnitev zakostenevanja pri plodovih, ki so bili zdravilu izpostavljeni in utero v drugi polovici nosečnosti, in pri otrocih, mlajših od osem let, zaradi kopičenja v tkivih z velikim obratom kalcija in nastajanja kompleksov kalcijevega kelata (glejte poglavje 4.4).
The reconstituted solution should be yellow to orange in colour; if not, the solution should be discarded.
Rekonstituirana raztopina mora biti rumene do oranžne barve; če raztopina ni take barve, jo morate zavreči.
Limited experience is also available in treating patients with concurrent bacteraemia (3.4 %).
Na voljo je tudi malo izkušenj z zdravljenjem bolnikov s sočasno bakteriemijo (3,4 %).
After reconstitution, 1 ml contains 10 mg of tigecycline.
Po rekonstituciji 1 ml vsebuje 10 mg tigeciklina.
Higher Cmax values than in adult patients were observed in several children in these studies.
Pri več otrocih v omenjenih študijah so ugotovili večje vrednosti Cmax kot pri odraslih.
Significant differences in sepsis/septic shock with tigecycline (2.2 %) vs comparators (1.1 %) were observed.
Opazili so pomembne razlike glede sepse/septičnega šoka med tigeciklinom (2,2 %) in primerjalnimi zdravili (1,1 %).
• Complicated infection of the skin and soft tissues (the tissue below the skin), excluding diabetic foot infections.
• zapleteno okužbo kože in mehkih tkiv (tkiva pod kožo), razen okužb diabetičnega stopala
Overgrowth of non-susceptible organisms, including fungi (see section 4.4).
Razraščanje neobčutljivih mikroorganizmov, vključno z glivicami (glejte poglavje 4.4).
• Poor or slow wound healing
• slabo ali počasno celjenje ran
The total clearance of tigecycline is 24 L/h after intravenous infusion.
Celotni očistek tigeciklina po intravenskem infundiranju je 24 l/h.
Clinical Cure, mITT Population 0.75 mg/kg
Klinična ozdravitev, populacija mITT 0,75 mg/kg 1 mg/kg 1,25 mg/kg
• If you are suffering from diarrhoea before you are given Tygacil.
• če imate drisko, še preden začnete prejemati zdravilo Tygacil.
When administered through a Y-site, compatibility of tigecycline diluted in sodium chloride 0.9 % for injection is demonstrated with the following medicinal products or diluents: amikacin, dobutamine, dopamine HCl, gentamicin, haloperidol, Lactated Ringer's, lidocaine HCl, metoclopramide, morphine, norepinephrine, piperacillin/tazobactam (EDTA formulation), potassium chloride, propofol, ranitidine HCl, theophylline, and tobramycin.
Kompatibilnost tigeciklina, razredčenega z 0,9-odstotnim natrijevim kloridom za injiciranje, pri injiciranju v podaljšek Y so dokazali za naslednja zdravila in vehikle: amikacin, dobutamin, dopaminijev hidroklorid, gentamicin, haloperidol, Ringerjev laktat, lidokainijev hidroklorid, metoklopramid, morfin, noradrenalin, piperacilin/tazobaktam (pripravek z EDTA), kalijev klorid, propofol, ranitidinijev hidroklorid, teofilin in tobramicin.
Read the package leaflet before use for directions on reconstitution and dilution.
Pred uporabo preberite priloženo navodilo, ki vsebuje navodila za rekonstitucijo in redčenje zdravila!
A patient developing impaired healing should be monitored for the detection of superinfection (see section 4.8).
Bolnike, pri katerih se razvije slabše celjenje, je treba spremljati zaradi odkrivanja superinfekcije (glejte poglavje 4.8).
S  0.25 mg/L and R  0.5 mg/L Enterobacteriaceae S  1
S  0,25 mg/l in R > 0,5 mg/l Enterobacteriaceae S  1
• Skin rash, which may lead to severe blistering and peeling of the skin (Stevens-Johnson
• kožni izpuščaj, ki lahko vodi do mehurjev in luščenja kože (Stevens-Johnsonov sindrom)
Elderly No dosage adjustment is necessary in elderly patients (see section 5.2).
Starejši bolniki Pri starejših bolnikih prilagajanje odmerka ni potrebno (glejte poglavje 5.2).
In clinical trials in cIAI, the most common type of infection in tigecycline-treated patients was complicated appendicitis (50.3 %), followed by other diagnoses less commonly reported such as complicated cholecystitis (9.6 %), perforation of intestine (9.6 %), intra-abdominal abscess (8.7 %), gastric or duodenal ulcer perforation (8.3 %), peritonitis (6.2 %) and complicated diverticulitis (6.0 %).
V kliničnih preskušanjih pri cIAI je bila najpogostejša vrsta okužb pri bolnikih, zdravljenih s tigeciklinom, vnetje slepiča z zapleti (50,3 %), sledile so mu druge diagnoze, o katerih so redkeje poročali, na primer vnetje žolčnika z zapleti (9,6 %), perforacija črevesa (9,6 %), intraabdominalni absces (8,7 %), perforacija želodčne ali duodenalne razjede (8,3 %), peritonitis (6,2 %) in zapleti divertikulitisa (6,0 %).
Based on an in vitro study tigecycline is a P-gp substrate.
Na podlagi in vitro študije je tigeciklin substrat P-gp.
However, since tigecycline may prolong both prothrombin time (PT) and activated partial thromboplastin time (aPTT), the relevant coagulation tests should be closely monitored when tigecycline is co-administered with anticoagulants (see section 4.4).
Ker pa lahko tigeciklin podaljša tako protrombinski čas (PČ) kot aktivirani parcialni tromboplastinski čas, moramo skrbno spremljati zadevne koagulacijske teste, kadar dajemo tigeciklin sočasno z antikoagulanti (glejte poglavje 4.4).
C-tigecycline, radioactivity was well distributed to most tissues, with the highest overall exposure observed in bone marrow, salivary glands, thyroid gland, spleen, and kidney.
C-tigeciklina, se je radioaktivnost dobro porazdelila v večino tkiv, pri čemer so največjo celotno izpostavljenost izmerili v kostnem mozgu, slinavkah, ščitnici, vranici in ledvici.
If you are concerned that you may have been given too much Tygacil, talk to your doctor or nurse immediately.
Če vas skrbi, da ste morda prejeli prevelik odmerek zdravila Tygacil, se nemudoma pogovorite z zdravnikom ali medicinsko sestro.
Powder for solution for infusion 10 vials
Prašek za raztopino za infundiranje 10 vial
In clinical trials in cSSTI, the most common type of infection in tigecycline treated-patients was cellulitis (58.6 %), followed by major abscesses (24.9 %).
V kliničnih preskušanjih pri cSSTI je bila najpogostejša vrsta okužbe pri bolnikih, zdravljenih s tigeciklinom, flegmona (58,6 %), ki so ji sledili večji abscesi (24,9 %).
Results of animal studies indicate that tigecycline crosses the placenta and is found in foetal tissues.
Rezultati študij na živalih kažejo, da tigeciklin prehaja skozi posteljico in ga najdemo v plodovih tkivih.
What Tygacil is and what it is used for What you need to know before you receive Tygacil How Tygacil is given
Kaj je zdravilo Tygacil in za kaj ga uporabljamo Kaj morate vedeti, preden boste prejeli zdravilo Tygacil Kako uporabljati zdravilo Tygacil Možni neželeni učinki
• Complicated infection in the abdomen
• zapleteno okužbo v trebuhu
There are no or limited amount of data from the use of tigecycline in pregnant women.
Podatkov o uporabi tigeciklina pri nosečnicah ni oziroma so omejeni.
Therefore, clearance of tigecycline is not expected to be affected by active substances that inhibit or induce the activity of the CYP450 isoforms.
Zato ni pričakovati, da bi učinkovine, ki zavirajo ali inducirajo aktivnost izoencimov CYP450, vplivale na očistek tigeciklina.
• Increases in liver enzymes, hyperbilirubinaemia (excess of bile pigment in the blood)
• zvišana raven jetrnih encimov, hiperbilirubinemija (zvišana raven žolčnega barvila v krvi)
Glucuronidation and renal excretion of unchanged tigecycline are secondary routes.
Glukuronidacija in izločanje nespremenjenega tigeciklina skozi ledvice sta manj pomembni poti.
Tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections (see sections 4.4 and 5.1):
Zdravilo Tygacil je indicirano pri odraslih in otrocih, starih 8 let ali več, za zdravljenje naslednjih okužb (glejte poglavji 4.4. in 5.1):
The safety of tigecycline was also investigated in an open-label, ascending multi-dose PK study in 58 children aged 8 to 11 years with cSSTI (n=15), cIAI (n=24) or community-acquired pneumonia (n=19).
Varnost tigeciklina so preučili tudi v odprti farmakokinetični študiji z večkratnim odmerjanjem s povečevanjem odmerka pri 58 otrocih, starih od 8 do 11 let, s cSSTI (n = 15), cIAI (n = 24) ali zunajbolnišnično pljučnico (n = 19).
Tygacil should not be used in children under 8 years of age due to the lack of safety and efficacy data in this age group and because tigecycline may be associated with permanent teeth discolouration (see sections 4.2 and 4.8).
Zdravila Tygacil ne smemo uporabljati pri otrocih, mlajših od 8 let, zaradi pomanjkanja podatkov o varnosti in učinkovitosti v tej starostni skupini in ker je uporaba tigeciklina lahko povezana s trajnim obarvanjem zob (glejte poglavji 4.2 in 4.8).
Results of studies in rats with tigecycline have shown bone discolouration.
Rezultati študij s tigeciklinom na podganah so pokazali obarvanje kosti.
Tigecycline did not affect mating or fertility in rats at exposures up to 4.7 times the human daily dose based on AUC.
Tigeciklin ni vplival na parjenje ali plodnost pri podganah pri izpostavljenostih, ki so bile do 4,7-krat večje od dnevnega odmerka za ljudi na podlagi AUC.
In an open-label, ascending multiple-dose study, 39 children aged 8 to 11 years with cIAI or cSSTI were administered tigecycline (0.75, 1, or 1.25 mg/kg).
V odprti študiji z večkratnim odmerjanjem s povečevanjem odmerka je 39 otrok, starih od 8 do 11 let, s cIAI ali cSSTI prejelo tigeciklin (0,75, 1 ali 1,25 mg/kg).
• Tell your doctor immediately if you develop severe abdominal pain, nausea, and vomiting.
• takoj povejte zdravniku, če se vam razvijejo hude bolečine v trebuhu, slabost s siljenjem na bruhanje (navzea) in bruhanje.
There is limited evidence of the clinical efficacy of tigecycline against enterococci.
Dokazov klinične učinkovitosti tigeciklina proti enterokokom je malo.
Overall, the primary route of elimination for tigecycline is biliary excretion of unchanged tigecycline.
V celoti gledano je primarna pot odstranjevanja tigeciklina iz telesa izločanje nespremenjenega tigeciklina z žolčem.
Although hepatic failure may occur in patients treated with tigecycline due to the underlying conditions or concomitant medicinal products, a possible contribution of tigecycline should be considered (see section 4.8).
Čeprav lahko pride do odpovedi jeter pri bolnikih, zdravljenih s tigeciklinom, zaradi osnovnih bolezni ali sočasnega prejemanja drugih zdravil, moramo upoštevati tudi možni prispevek tigeciklina (glejte poglavje 4.8).
Tygacil should not be used in children aged under 8 years because of teeth discolouration (see sections 4.4 and 5.1).
Zdravila Tygacil se ne sme uporabljati pri otrocih, mlajših od 8 let, zaradi obarvanja zob (glejte poglavji 4.4 in 5.1).
It is not known if Tygacil passes into breast milk in humans.
Ni znano, če zdravilo Tygacil pri ljudeh prehaja v materino mleko.
5 ml Type 1 clear glass vials fitted with grey butyl rubber stoppers and snap-off aluminium crimp seals.
5-mililitrske steklene viale iz prozornega stekla tipa 1, zaprte z zamaškom iz sive butilne gume in aluminijasto zaporko.
Digoxin did not affect the pharmacokinetic profile of tigecycline.
Digoksin ni vplival na farmakokinetični profil tigeciklina.
The Tygacil solution should be yellow to orange in colour after dissolving; if it is not, the solution should be discarded.
Raztopina zdravila Tygacil mora biti po raztapljanju rumene do oranžne barve; če raztopina ni take barve, jo je treba zavreči.
Metabolism and nutrition disorders hypoglycaemia, hypoproteinaemia
Presnovne in prehranske motnje hipoglikemija, hipoproteinemija
Patients hypersensitive to tetracycline class antibiotics may be hypersensitive to tigecycline.
Bolniki, ki so preobčutljivi za antibiotike tetraciklinske skupine, so lahko preobčutljivi na tigeciklin.
How to store Tygacil
Kako uporabljati zdravilo Tygacil
Tigecycline is vulnerable to chromosomally-encoded multi-drug efflux pumps of Proteeae and Pseudomonas aeruginosa.
Tigeciklin je dovzeten za kromosomsko kodirane multimedikamentozne iztočne črpalke družine Proteeae in vrste Pseudomonas aeruginosa.
Co-administration of P-gp inhibitors (e.g., ketoconazole or cyclosporine) or P-gp inducers (e.g., rifampicin) could affect the pharmacokinetics of tigecycline.
Sočasna uporaba inhibitorjev P-gp (npr. ketokonazola ali ciklosporina) ali induktorjev P-gp (npr. rifampicina) bi lahko vplivala na farmakokinetiko tigeciklina.
Glycylcycline class antibiotics are structurally similar to tetracycline class antibiotics.
Antibiotiki glicilciklinske skupine so po zgradbi podobni antibiotikom tetraciklinske skupine.
Tigecycline is not removed in significant quantities by haemodialysis.
Tigeciklin se s hemodializo ne odstrani v pomembnih količinah.
• Low blood sugar
• znižana raven sladkorja v krvi